Clinical Trials
8 trialsNCT05827614 2026-06-08
POTENTIATE
Boundless Bio, Inc.
Phase 1 Terminated
NCT05727176 2026-05-28
FOENIX-CCA4
Taiho Oncology, Inc.
Phase 2 Recruiting
NCT06506955 2026-05-28
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT04507503 2026-03-10
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Approved for marketing
NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04024436 2025-11-13
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04189445 2025-10-08
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
Phase 2 Terminated